Liquid Chromatographic Method for the Simultaneous Determination of Eprosartan and Hydrochlorothiazide in Tablets and Human PlasmaBELAL, Fathalla; EL-BRASHY, Amina M; EL-ENANY, Nahed et al.Journal of AOAC International. 2011, Vol 94, Num 3, pp 823-832, issn 1060-3271, 10 p.Article

Development and Validation of a High-Performance Liquid Chromatographic Method for Determination of Eprosartan in Bulk Drug and TabletsPATEL, Harsha U; SUHAGIA, Bhanubhai N; PATEL, Chhaganbhai N et al.Journal of AOAC International. 2010, Vol 93, Num 6, pp 1862-1867, issn 1060-3271, 6 p.Article

AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gainHEUSSER, Karsten; VITKOVSKY, Jan; SCHMIEDER, Roland E et al.Autonomic neuroscience : basic & clinical. 2003, Vol 107, Num 1, pp 45-51, issn 1566-0702, 7 p.Article

Pharmacology of eprosartan, an angiotensin II receptor antagonist : Exploring hypotheses from clinical dataBROOKS, D. P; OHLSTEIN, E. H; RUFFOLO, R. R et al.The American heart journal. 1999, Vol 138, Num 3, pp S246-S251, issn 0002-8703, 2Article

Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteersISRAEL, Anita; ZAVALA, Lida E; CIERCO, Maria et al.Autonomic neuroscience : basic & clinical. 2006, Vol 126-27, pp 179-184, issn 1566-0702, 6 p.Conference Paper

A dose proportionality study of eprosartan in healthy male volunteersCHAPELSKY, M. C; MARTIN, D. E; TENERO, D. M et al.Journal of clinical pharmacology. 1998, Vol 38, Num 1, pp 34-39, issn 0091-2700Article

Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy menPRICE, D. A; DE'OLIVEIRA, J. M; FISHER, N. D. L et al.Hypertension (Dallas, Tex. 1979). 1997, Vol 30, Num 2, pp 240-246, issn 0194-911X, 1Article

Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertensionGRADMAN, A. H; GRAY, J; MAGGIACOMO, F et al.Clinical therapeutics. 1999, Vol 21, Num 3, pp 442-453, issn 0149-2918Article

Efficacy and safety of eprosartan in severe hypertensionSEGA, R.Blood pressure. 1999, Vol 8, Num 2, pp 114-121, issn 0803-7051Article

Clinical profile of eprosartanGARCIA PUIG, Juan; MARTINEZ LOPEZ, Maria A; SANCHO BUESO, Teresa et al.Cardiovascular drugs and therapy. 2002, Vol 16, Num 6, pp 543-549, issn 0920-3206, 7 p.Article

Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonistsSONG, J. C; WHITE, C. M.Pharmacotherapy. 2000, Vol 20, Num 2, pp 130-139, issn 0277-0008Article

Safety and efficacy of eprosartan, a new angiotensin II receptor blockerSHUSTERMAN, N. H.The American heart journal. 1999, Vol 138, Num 3, pp S238-S245, issn 0002-8703, 2Article

Eprosartan does not affect the pharmacodynamics of warfarinKAZIERAD, D. J; MARTIN, D. E; ILSON, B et al.Journal of clinical pharmacology. 1998, Vol 38, Num 7, pp 649-653, issn 0091-2700Article

Eprosartan. CommentaryMCCLELLAN, K. J; BALFOUR, J. A; HIMMELMANN, Y. A et al.Drugs (Basel). 1998, Vol 55, Num 5, pp 713-720, issn 0012-6667Article

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairmentMARTIN, D. E; CHAPELSKY, M. C; ILSON, B et al.Journal of clinical pharmacology. 1998, Vol 38, Num 2, pp 129-137, issn 0091-2700Article

Effects of eprosartan on mitochondrial membrane potential and H₂O₂ levels in leucocytes in hypertensionLABIOS, M; MARTINEZ, M; GABRIEL, F et al.Journal of human hypertension. 2008, Vol 22, Num 7, pp 493-500, issn 0950-9240, 8 p.Article

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter studyPUNZI, H. A; PUNZI, C. F.Journal of human hypertension. 2004, Vol 18, Num 9, pp 655-661, issn 0950-9240, 7 p.Article

Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertensionLABIOS, Manuel; MART'NEZ, Marcial; GABRIEL, Francisco et al.American journal of hypertension. 2004, Vol 17, Num 9, pp 757-763, issn 0895-7061, 7 p.Article

Eprosartan^(Teveten®⁾: HTA: 6^e antagoniste de l'angiotensine II, pas de progrès = Eprosartan⁽Teveten®): HTA: 6^th angiotensinII antagonist, no progressLa Revue Prescrire. 2001, Vol 21, Num 218, pp 412-413, issn 0247-7750Article

A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT₁-receptor antagonist, in sodium-replete healthy menILSON, B. E; BOIKE, S. C; MARTIN, D. E et al.Clinical pharmacology and therapeutics. 1998, Vol 63, Num 4, pp 471-481, issn 0009-9236Article

Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertensionLEVINE, Barton.Current medical research and opinion. 2001, Vol 17, Num 1, pp 8-17, issn 0300-7995Article

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertensionPUIG, J. G; MATEOS, F; BUNO, A et al.Journal of hypertension. 1999, Vol 17, Num 7, pp 1033-1039, issn 0263-6352Article

Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stressAROSIO, Enrico; DE MARCHI, Sergio; PRIOR, Manlio et al.Journal of hypertension. 2005, Vol 23, Num 10, pp 1923-1927, issn 0263-6352, 5 p.Article

Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertensionWHITE, William B; YUSRA ANIS ANWAR; MANSOOR, George A et al.American journal of hypertension. 2001, Vol 14, Num 12, pp 1248-1255, issn 0895-7061Article

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal diseaseKOVACS, S. J; TENERO, D. M; MARTIN, D. E et al.Pharmacotherapy. 1999, Vol 19, Num 5, pp 612-619, issn 0277-0008Article